PHILADELPHIA, PA. Feb. 3, 2025 Vetigenics, a clinical-stage animal health biotechnology company specializing in antibody therapeutics for pets, announces significant progress over the past year, including closing a $6 million seed round and advancing multiple clinical-stage programs.
Read More